James Breitmeyer - Chief Executive Officer, Oncternal Therapeutics, Inc

As of January 31, 2022


What is James Breitmeyer's Net Worth?

The current estimated net worth of Oncternal Therapeutics, Inc's Chief Executive Officer, James Breitmeyer, is estimated to be about $568.75K . James Breitmeyer owns about 47,277 units of Oncternal Therapeutics, Inc common stock. In the last 3 years at Oncternal Therapeutics, Inc, James Breitmeyer has sold an estimated value of $0 worth.

What is James Breitmeyer's Past Insider Trading?

James Breitmeyer's largest purchase order was 25,000 units , worth over $42.08K on January 31, 2022. In total, James Breitmeyer has made about 11 transactions over 3 years of their time at Oncternal Therapeutics, Inc. James Breitmeyer usually trades in January, with the busiest year in 2021, 2019 and 2022.

Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1

What are Oncternal Therapeutics, Inc's Past Insider Trades?

Oncternal Therapeutics, Inc's most recent insider trade came on March 28, 2022 by Richard Vincent who bought 5,000 units worth $7.21K . In the last 2 years, insiders at Oncternal Therapeutics, Inc have sold an estimated value of $17.43K and bought an estimated value of $2.89M worth of shares. Insider trading is most common in June, with the busiest year in 2022. The most active traders at the company are James Breitmeyer, Chief Executive Officer,  Richard Vincent, Chief Financial Officer,  and David Hale, Director .

Oncternal Therapeutics, Inc. Insider Trades

Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1